Buspirone ameliorates premature ovarian insufficiency evoked by cyclophosphamide in female rats; attention to AMPK/Nrf2/HO-1, α-Klotho/NLRP3/Caspase-1, and Caspase-3-mediated apoptosis interplay
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
Buspirone treatment reversed cyclophosphamide-induced premature ovarian insufficiency in rats by modulating AMPK/Nrf2/HO-1, α-Klotho/NLRP3/Caspase-1 pathways and reducing apoptosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
This study aims to investigate the protective impact of buspirone (BUS) against cyclophosphamide (CPA)-induced premature ovarian insufficiency (POI) by focusing on pyroptosis, apoptosis, and the AMPK/Nrf2/HO-1 signaling pathway. POI was achieved by i.p. injection of CPA in female Wistar albino rats. CPA toxicity was evaluated using biochemical analysis of the serum hormones (AMH, FSH, inhibin B, and estrogen) and histopathological examination. Oxidative stress markers (MDA, SOD) were also evaluated. Levels of inflammatory indicators (TNF-α, IL-1β, and IL-18), apoptotic marker (caspase-3), ovarian p-AMPK, ovarian NF-κB, Nrf2, and HO-1 were evaluated. RT-qPCR was used to measure Bax and Bcl-2 mRNA expression. A western blot assay was used to determine the expression of α-Klotho, NLRP3, and caspase 1. The estrous cycle and the weights of the body and ovaries were also observed. BUS, in a dose-dependent manner, attenuated CPA-induced ovarian toxicity by regulating hormonal and estrous cycle irregularities and alleviating the histopathological aberrations. It also lowered MDA levels and increased SOD activity. Furthermore, it reduced NF-κB, TNF-α, IL-1β, and IL-18 levels, as well as BAX and caspase-3 expression, while raising Bcl-2 levels. Additionally, BUS enhanced Nrf2 and HO-1 expression and boosted the protein levels of p-AMPK and α-Klotho. As well, it diminished pyroptosis by decreasing NLRP3 and caspase-1 expression. BUS attenuated POI induced by CPA, showing potential for effective protection via increasing the activity of Nrf2/HO-1 and reducing the activity of NLRP3/Caspase-1 through the participation of α-Klotho and p-AMPK, as well as inhibiting caspase-3-driven apoptosis.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- ESHRE Guideline: management of women with premature ovarian insufficiency 2016
- Moxibustion mitigates mitochondrial dysfunction and NLRP3 inflammatory activation in cyclophosphamide-induced premature ovarian insufficiency rats 2022
- The effect of Bu Shen Huo Xue Tang on autoimmune premature ovarian insufficiency via Modulation of the Nrf2/Keap1 signaling pathway in mice 2021
- Psychological stressors involved in the pathogenesis of premature ovarian insufficiency and potential intervention measures 2024
Cited by (2)
References (100)
- ESHRE Guideline: management of women with premature ovarian insufficiency via openalex
- Moxibustion mitigates mitochondrial dysfunction and NLRP3 inflammatory activation in cyclophosphamide-induced premature ovarian insufficiency rats via openalex
- Psychological stressors involved in the pathogenesis of premature ovarian insufficiency and potential intervention measures via openalex
- The effect of Bu Shen Huo Xue Tang on autoimmune premature ovarian insufficiency via Modulation of the Nrf2/Keap1 signaling pathway in mice via openalex
- W1964406604 via openalex
- W1972518291 via openalex
- W1979467526 via openalex
- W1979617003 via openalex
- W1999289481 via openalex
- W2012875012 via openalex
- W2020326519 via openalex
- W2021119759 via openalex
- W2029490482 via openalex
- W2031942208 via openalex
- W2034172400 via openalex
- W2035255299 via openalex
- W2037196867 via openalex
- W2043731235 via openalex
- W2066404322 via openalex
- W2096022216 via openalex
- W2105725429 via openalex
- W2109012795 via openalex
- W2111387994 via openalex
- W2128780026 via openalex
- W2131692421 via openalex
- W2147380695 via openalex
- W2169915553 via openalex
- W2195384405 via openalex
- W2220816374 via openalex
- W2317166072 via openalex
- W2335138225 via openalex
- W2409103152 via openalex
- W2414056075 via openalex
- W2415521731 via openalex
- W2515590801 via openalex
- W2606232917 via openalex
- W2613649827 via openalex
- W2735417387 via openalex
- W2749523171 via openalex
- W2773293891 via openalex
- W2791956178 via openalex
- W2803303442 via openalex
- W2808100865 via openalex
- W2884445384 via openalex
- W2898820869 via openalex
- W2904149902 via openalex
- W2904759662 via openalex
- W2905546187 via openalex
- W2958279967 via openalex
- W2964461736 via openalex
- W2968694758 via openalex
- W2982686492 via openalex
- W3017324284 via openalex
- W3042005913 via openalex
- W3044438408 via openalex
- W3048391838 via openalex
- W3084973152 via openalex
- W3092412447 via openalex
- W3096050386 via openalex
- W3107789569 via openalex
- W3110676004 via openalex
- W3117264815 via openalex
- W3120229241 via openalex
- W3128646645 via openalex
- W3128991791 via openalex
- W3132651071 via openalex
- W3134821296 via openalex
- W3164994963 via openalex
- W3177319807 via openalex
- W3185082983 via openalex
- W3191851278 via openalex
- W3211804812 via openalex
- W4200230769 via openalex
- W4205804402 via openalex
- W4211047546 via openalex
- W4212986000 via openalex
- W4213324468 via openalex
- W4221096450 via openalex
- W4226467585 via openalex
- W4229456001 via openalex
- W4282586889 via openalex
- W4285091670 via openalex
- W4289516794 via openalex
- W4294219464 via openalex
- W4297364498 via openalex
- W4310974111 via openalex
- W4311283153 via openalex
- W4313244994 via openalex
- W4313250827 via openalex
- W4317359002 via openalex
- W4318191417 via openalex
- W4321381935 via openalex
- W4321787470 via openalex
- W4323667880 via openalex
- W4324262865 via openalex
- W4365443417 via openalex
- W4376879251 via openalex
- W4381469193 via openalex
- W4385454266 via openalex
- W4385616378 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK